This study is for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has a change in a gene called MET exon 14 skipping. In this study, doctors will test two medicines: tepotinib and ramucirumab. Tepotinib blocks a protein that helps cancer cells grow, while ramucirumab stops new blood vessels that cancer needs to grow. The study is for people whose cancer has come back or spread to other parts of the body. Participants will be given either tepotinib alone or with ramucirumab, and will have regular check-ups and scans to see how the treatment is working.

• The trial involves taking medicine by mouth and/or through an IV every 21 days.
• Participants will have regular scans and blood tests to monitor progress.
• After treatment, follow-up visits occur every 12 weeks, then every 6 months for up to 3 years.

Eligibility includes having the specific gene change, prior lung cancer treatments, and no recent major surgeries or other treatments. Participants must agree to use contraception if needed and not be pregnant or breastfeeding. This study aims to see if these medicines can help slow or stop cancer from growing.